Table 3.
Effect of oridonin on receptors, enzymes, and protein expression
| Receptor/enzyme/proteins | Cellular model | Effect | References |
|---|---|---|---|
| P53, Bax | LNCap cells | Upregulation | [34] |
| Bcl-2 | LNCap cells | Downregulation | [34] |
| Androgen receptor | Carcinoma A431 | Downregulation | [78] |
| Bax proteins | LNCap cells | Induction | [79] |
| Bax/Bcl-2 ratio and cytochrome c | HeLa cells | Induction | [80] |
| HSP 70 | Jurkat cells | Inhibition | [81] |
| Nrf2 | UROtsa cells | Activation | [37] |
| P16, p21, p27 and c-myc | Colorectal cancer cells | Regulation | [38] |
| HO-1 | Rat splenic lymphocytes | Induction | [18] |
| c-Myc | Cancer cells | Reduction of protein levels | [22] |
| Pro-TNFalpha expression and IkB phosphorylation | L929 fibrosarcoma cells | Induction | [23] |
| P53, Bcl-2 | L929 cells | Promotes phosphorylation of p53 and increased Bax expression | [82] |
| AKT, FOXO transcription factor and GSK3 | Human osteosarcoma cells | Dephosphorylation | [26] |
| EGFR | Human laryngeal cancer cells | Augmentation of apoptosis induction | [83] |
| Fatty acid synthase | Human colorectal cancer cells | Suppression | [84] |
| Tyrosine kinase and EGFR | Human epidermoid carcinoma A431 cells | Decrease in tyrosine kinase activity and blockage of EGFR | [85] |
| Telomerase | K562 cells | Inhibition | [86] |
| Bcl-2 | Lung cancer cell line SPC-A-1 | Downregulation | [5] |
| IL2, IFN gamma, IL12p40, and TNF alpha | Murine splenic lymphocytes | Inhibition | [55] |
| Bax | Lung cancer cell line SPC A-1 | Upregulation | [5] |
| Caspase-3-zymogen protein, Bcl-2, and Bcl-XL | HPB-ALL cells | Downregulation | [28] |
| Telomerase, Bcl-2 | K562 cells | Downregulation | [54] |
| Bax | K562 cells | Upregulation | [54] |
| Telomerase | HL-60 cells | Downregulation | [87] |
| hTERT mRNA, and telomerase | HL-60 cells | Dowregulation | [88] |
| Bcl-2/Bax ratio | A549 cells | Induction of ratio decrease | [56] |
| PI3K, PKC, and ERK | Macrophage-like U937 cells | Activation | [40] |
| TNF alpha, IL-1 beta | Macrophage-like U937 cells | Release | [89] |
| Apaf-1, cytochrome c, and caspase-3 | Gastric cancer cell line HGC-27 | Induction | [90] |
| p-JNK, p-p38, p-p53, and p21 | HepG2 cells | Incretion | [42] |
| B1/p-Cdc2 (Tyr15) complex | HepG2 cells | Increase | [42] |
| Hsp70.1, STRAP, TCTP,Sti1 and PPase | HepG2 cells | Upregulation | [29] |
| hnRNP-E1 | HepG2 cells | Downregulation | [29] |
| Bcl-2/Bax ratio, caspase-8, NF-kappa B(p65), IKKalpha, phospho-mTOR | Human breast cancer cells | Reduction | [57] |
| Cleaved PARP, Fas, and PPAR gamma | Human breast cancer cells | Increase | [57] |
| NO, TNF alpha, IL6 | LPS-activated microglia | Inhibition | [45] |
| Nucleoporin 88 and 214 | OCIM2 acute erythroleukemia cells | Protection from apoptosis | [91] |
| SIRT1 | Human multiple myeloma cells | Regulation | [30] |
| Raf-1, JNK, and p-JNK | HeLa cells | Induction | [92] |
| BAFF | mice | Inhibition | [93] |
| BIM | Melanoma OCM-1 and MUM2B cell lines | Upregulation | [110] |
| Fatty acid synthase | Melanoma OCM-1 and MUM2B cell lines | Downregulation | [110] |
| PARP | BXPC-3 cells | Induction | [111] |
AKT protein kinase B, BAFF B-cell activating factor, Bcl B-cell lymphoma, EGFR epidermal growth factor receptor, FOXO forkhead box O, GSK3 glycogen synthase kinase 3, hnRNP heterogeneous ribonucleoprotein, HSP heat shock protein, hTERT human telomerase reverse transcriptase, IFN interferon, IL interleukin, mRNA messenger RNA, mTOR mammalian target of rapamycin, NO nitric oxide, PARP poly (ADP-ribose) polymerase, PI3 phosphatidylinositol-3, PKC protein kinase 3, PPAR peroxisome proliferator-activated receptor, PPase protein phosphatase, STRAP serine/threonine kinase receptor-associated protein, TCTP translationally controlled tumour protein, TNF tumor necrosis factor